Tim Tasker
2021
Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study
2021 • C. J. G. Bakker, Tim Tasker, Jan Liptrot, Ellen P. Hart, Erica S. Klaassen, Robert J. Doll, Giles A. Brown, Alastair Brown, Miles Congreve, Malcolm...
2021
Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M<sub>1</sub>‐acetylcholine receptor agonist: A randomized cross‐over trial
2021 • C. J. G. Bakker, Samantha Prins, Jan Liptrot, Ellen P. Hart, Erica S. Klaassen, Giles A. Brown, Alastair Brown, Miles Congreve, Malcolm Weir, Fiona...
2020
First‐in‐man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M<sub>1</sub>‐receptor partial agonist for the treatment of dementias
2020 • C. J. G. Bakker, Tim Tasker, Jan Liptrot, Ellen P. Hart, Erica S. Klaassen, Samantha Prins, Thalia F. van der Doef, Giles A. Brown, Alastair Brown,...
2019
P3‐025: USE OF A MODIFIED HIDDEN PATHWAY MAZE TEST IN PATIENTS WITH ALZHEIMER'S DISEASE DEMENTIA
2019 • Chris J. Edgar, Tim Tasker, Adrian Schembri, Babli Millais, Bharat Ruparelia, Odile Dewit, Stephen Jones, Paul Maruff, Pradeep J. Nathan
2022
A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M <sub>1</sub> receptor agonist HTL0018318 in patients with mild‐to‐moderate Alzheimer's disease
2022 • Pradeep J. Nathan, S. Babli Millais, A. Godwood, Odile Dewit, David M. Cross, J. Liptrot, Bharat Ruparelia, Stephen P. Jones, Geor Bakker, Paul Mar...
Open Author Page
Exploring foci of
2022-01-01
A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M <sub>1</sub> receptor agonist HTL0018318 in patients with mild‐to‐moderate Alzheimer's disease
2022-01-01 • Pradeep J. Nathan, S. Babli Millais, A. Godwood, Odile Dewit, David M. Cross, J. Liptrot, Bharat Ruparelia, Stephen P. Jones, Geor Bakker, Paul Mar...
Abstract Introduction This study examined the safety and pharmacodynamic effects of selective muscarinic M 1 receptor orthosteric agonist HTL0018318 in 60 patients with mild‐to‐moderate Alzheimer's disease (AD) on background donepezil 10 mg/day. Methods A randomized, double‐blind, placebo‐controlled 4‐week safety study of HTL0018318 with up‐titration and maintenance phases, observing exploratory effects on electrophysiological biomarkers and cognition. Results Treatment‐emergent adverse events (TEAEs) were mild an…
Open Article Page
Delayed Sleep Phase Disorder
Study After Velázquez's Portrait Of Pope Innocent X
In-Phase And Quadrature Components
Phase-Locked Loop
Observational Study
Genome-Wide Association Study
Institute For Advanced Study
Single-Phase Electric Power
2017–18 Uefa Champions League Knockout Phase
Open Article Page
Exploring foci of
2021-04-21
Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study
2021-04-21 • C. J. G. Bakker, Tim Tasker, Jan Liptrot, Ellen P. Hart, Erica S. Klaassen, Robert J. Doll, Giles A. Brown, Alastair Brown, Miles Congreve, Malcolm...
Abstract Background The cholinergic system and M 1 receptor remain an important target for symptomatic treatment of cognitive dysfunction. The selective M 1 receptor partial agonist HTL0018318 is under development for the symptomatic treatment of Dementia’s including Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB). We investigated the safety, tolerability, pharmacokinetics and exploratory pharmacodynamics of multiple doses of HTL0018318 in healthy younger adults and elderly subjects. Methods This rand…
Open Article Page
Mobile Phones And Driving Safety
Committee Of Public Safety
Exploratory Factor Analysis
Hydrogen Safety
Fire Safety
Law Enforcement Officers Safety Act
Everytown For Gun Safety
Gun Safety
Food Safety And Standards Authority Of India
Open Article Page
Exploring foci of
2021-04-23
Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M<sub>1</sub>‐acetylcholine receptor agonist: A randomized cross‐over trial
2021-04-23 • C. J. G. Bakker, Samantha Prins, Jan Liptrot, Ellen P. Hart, Erica S. Klaassen, Giles A. Brown, Alastair Brown, Miles Congreve, Malcolm Weir, Fiona...
Aims HTL0009936 is a selective M 1 muscarinic receptor agonist in development for cognitive dysfunction in Alzheimer's disease. Safety, tolerability and pharmacokinetics and exploratory pharmacodynamic effects of HTL0009936 administered by continuous IV infusion at steady state were investigated in elderly subjects with below average cognitive functioning (BACF). Methods Part A was a four‐treatment open label sequential study in healthy elderly investigating 10–83 mg HTL0009936 (IV) and a 24 mg HTL0009936 single o…
Open Article Page
Mobile Phones And Driving Safety
Committee Of Public Safety
Everytown For Gun Safety
Safety Car
Intrinsic Safety
Safety Engineering
Chemical Safety
Automotive Safety
Child Safety Seat
Open Article Page
Exploring foci of
2020-12-23
First‐in‐man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M<sub>1</sub>‐receptor partial agonist for the treatment of dementias
2020-12-23 • C. J. G. Bakker, Tim Tasker, Jan Liptrot, Ellen P. Hart, Erica S. Klaassen, Samantha Prins, Thalia F. van der Doef, Giles A. Brown, Alastair Brown,...
Aims HTL0018318 is a selective M 1 receptor partial agonist currently under development for the symptomatic treatment of cognitive and behavioural symptoms in Alzheimer's disease and other dementias. We investigated safety, tolerability, pharmacokinetics and exploratory pharmacodynamics (PD) of HTL0018318 following single ascending doses. Methods This randomized, double‐blind, placebo‐controlled study in 40 healthy younger adult and 57 healthy elderly subjects, investigated oral doses of 1–35 mg HTL0018318. Pharma…
Open Article Page
First Battle Of Panipat
First Kill (2017 Film)
First Canadian Place
First Impressions Of Earth
First Inauguration Of Franklin D. Roosevelt
Murder In The First (Tv Series)
Infamous First Light
United States Court Of Appeals For The First Circuit
First Party System
Open Article Page
Exploring foci of
2019-07-01
P3‐025: USE OF A MODIFIED HIDDEN PATHWAY MAZE TEST IN PATIENTS WITH ALZHEIMER'S DISEASE DEMENTIA
2019-07-01 • Chris J. Edgar, Tim Tasker, Adrian Schembri, Babli Millais, Bharat Ruparelia, Odile Dewit, Stephen Jones, Paul Maruff, Pradeep J. Nathan
Maze tests have a long history as measures of visuospatial learning and executive function. The importance of impairments in both visuospatial learning and executive dysfunction has been increasingly recognized in early AD. In contrast to presented mazes, hidden pathway mazes use underlying rule sets to create decision points meaning additional data, such as different types of error, are obtained and can be used to more fully characterize performance and cognitive impairment. Computerized versions (e.g. the Groton…
Open Article Page
Hidden Bodies
Hidden Love
Modified Starch
Genetically Modified Food Controversies
Hidden Places
Nigrostriatal Pathway
Genetically Modified Crops
Among The Hidden
Genetically Modified Tomato
Open Article Page